Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy are holding back sales at the pharma ...

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

Company cuts 9,000 jobs and lowers profit forecast as Wegovy sales slow. Q3 operating profit down 30% on competition ...

Over 24% of Indian adults across all states are now considered overweight or obese with more than 12.5 million children under ...

“Lifestyle changes are associated with modest improvements in sperm motility and morphology, even though the amount of weight ...

The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.

The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar ...

In results published on November 5, the Danish pharmaceutical group said it now expects sales growth of 8–11 per cent at constant exchange rates.

Novo Nordisk agrees to IRA price caps for Ozempic, Wegovy under Medicare in 2027. Get key sales, profit impacts, and market outlook.

A glossy blue pill called “Molecule” is flooding Russian social feeds — promising hunger-free weight loss for the price of a coffee. But hidden inside the “natural” mix is sibutramine, a banned drug ...

Novo Nordisk is continuing to lose ground in the obesity and diabetes markets, with the Danish drugmaker saying it expected ...